This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bhaskar, V. Articles by Ramakrishnan, V. Search for Related Content PubMed PubMed Citation Articles by Bhaskar, V. Articles by Ramakrishnan, V.

E-Selectin Up-Regulation Allows for Targeted Drug Delivery in Prostate Cancer¹

Protein Design Labs, Inc., Fremont, California 94555 [V. B., D. A. L., E. I., D. B., R. B. D., F. E., J. C. M., M. P., R. P., U. v. F-J., R. M., D. E. H. A., V. R.]; Garvan Institute of Medical Research, St. Vincent’s Hospital, Darlinghurst, Sydney, NSW 2010, Australia [S. M. H., R. L. S.]; Seattle Genetics, Inc., Bothell, Washington 98021 [P. S.]; and Eos Biotechnology, Inc., South San Francisco, California 94080 [K. M. C., P. H., D. S., D. W.]

We have used the Eos Hu03 GeneChip array, which represents over 92% of the transcribed human genome, to measure gene expression in a panel of normal and diseased human tissues. This analysis revealed that E-selectin mRNA is selectively overexpressed in prostate cancer epithelium, a finding that correlated strongly with E-selectin protein expression as assessed by immunohistochemistry. Antibodies against E-selectin that blocked function failed to impede cancer cell growth, suggesting that overexpression of E-selectin was not essential for cell growth. However, a novel auristatin E-based antibody drug conjugate (ADC), E-selectin antibody valine-citrulline monomethyl-auristatin E, was a potent and selective agent against E-selectin-expressing cancer cell lines in vitro, with the degree of cytotoxicity varying with surface antigen density. Interestingly, sensitivity to the ADC differed among cell lines from different tissues expressing similar amounts of E-selectin and was found to correlate with sensitivity to free auristatin E. Furthermore, E-selectin-expressing tumors grown as xenografts in severe combined immunodeficient mice were responsive to treatment with E-selectin antibody valine-citrulline monomethyl-auristatin E in vivo, with more than 85% inhibition of tumor growth observed in treated mice. These findings demonstrate that an E-selectin-targeting ADC has potential as a prostate cancer therapy and validates a genomics-based paradigm for the identification of cancer-specific antigens suitable for targeted therapy.

This article has been cited by other articles:

				S. E. James, P. D. Greenberg, M. C. Jensen, Y. Lin, J. Wang, B. G. Till, A. A. Raubitschek, S. J. Forman, and O. W. Press Antigen Sensitivity of CD22-Specific Chimeric TCR Is Modulated by Target Epitope Distance from the Cell Membrane J. Immunol., May 15, 2008; 180(10): 7028 - 7038. [Abstract] [Full Text] [PDF]

				P. R. Reynolds, D. J. Larkman, D. O. Haskard, J. V. Hajnal, N. L. Kennea, A. J. T. George, and A. D. Edwards Detection of Vascular Expression of E-selectin in Vivo with MR Imaging Radiology, November 1, 2006; 241(2): 469 - 476. [Abstract] [Full Text] [PDF]

				C. F. McDonagh, E. Turcott, L. Westendorf, J. B. Webster, S. C. Alley, K. Kim, J. Andreyka, I. Stone, K. J. Hamblett, J. A. Francisco, et al. Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment Protein Eng. Des. Sel., July 1, 2006; 19(7): 299 - 307. [Abstract] [Full Text] [PDF]

				R. J. Sanderson, M. A. Hering, S. F. James, M. M.C. Sun, S. O. Doronina, A. W. Siadak, P. D. Senter, and A. F. Wahl In vivo Drug-Linker Stability of an Anti-CD30 Dipeptide-Linked Auristatin Immunoconjugate Clin. Cancer Res., January 15, 2005; 11(2): 843 - 852. [Abstract] [Full Text] [PDF]

				P. Carter, L. Smith, and M. Ryan Identification and validation of cell surface antigens for antibody targeting in oncology Endocr. Relat. Cancer, December 1, 2004; 11(4): 659 - 687. [Abstract] [Full Text] [PDF]

				D. E.H. Afar, V. Bhaskar, E. Ibsen, D. Breinberg, S. M. Henshall, J. G. Kench, M. Drobnjak, R. Powers, M. Wong, F. Evangelista, et al. Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer Mol. Cancer Ther., August 1, 2004; 3(8): 921 - 932. [Abstract] [Full Text] [PDF]

				T. Nubel, W. Dippold, B. Kaina, and G. Fritz Ionizing radiation-induced E-selectin gene expression and tumor cell adhesion is inhibited by lovastatin and all-trans retinoic acid Carcinogenesis, August 1, 2004; 25(8): 1335 - 1344. [Abstract] [Full Text] [PDF]